A Phase III randomised, double-blind study to evaluate the efficacy, safety and tolerability of simeprevir vs telaprevir in combination with pegylated interferon and ribavirin in chronic hepatitis C virus genotype 1 treatment-experienced patients: the ATTAIN study - Reddy, K; Zeuzem, S; Zoulim, F (Hepatol Int, 2014)
et al.